Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.63)
# 874
Out of 4,581 analysts
515
Total ratings
47.6%
Success rate
11.6%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics | Reiterated: Buy | $29 → $20 | $9.75 | +105.13% | 18 | Jul 27, 2026 | |
| MPLT MapLight Therapeutics | Maintained: Buy | $35 → $24 | $15.05 | +59.47% | 3 | Jul 27, 2026 | |
| HELP Cybin | Reiterated: Buy | $42 | $8.04 | +422.39% | 24 | Jul 22, 2026 | |
| ATAI AtaiBeckley | Reiterated: Buy | $17 → $8 | $7.18 | +11.50% | 23 | Jul 17, 2026 | |
| BIIB Biogen | Reiterated: Buy | $245 | $208.98 | +17.24% | 83 | Jul 15, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $12 | $3.05 | +294.09% | 39 | Jul 14, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $20 | $10.99 | +81.98% | 24 | Jul 8, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $32 → $36 | $26.25 | +37.14% | 52 | Jun 29, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $60 → $58 | $42.15 | +37.60% | 17 | Jun 29, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $21 | $13.57 | +54.75% | 4 | Jun 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $2.48 | +988.71% | 20 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $4.84 | +934.13% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $28.29 | +37.86% | 17 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $29.24 | +105.23% | 16 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $181.63 | +10.11% | 41 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $1.72 | +891.25% | 11 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $0.8101 | +2,121.95% | 55 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $2.37 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $12 | $21.47 | n/a | 12 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $31.25 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $34.63 | n/a | 9 | Jan 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $17.87 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $19.09 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $10.42 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $197.39 | $6.34 | n/a | 7 | Dec 18, 2015 |
Zevra Therapeutics
Jul 27, 2026
Reiterated: Buy
Price Target: $29 → $20
Current: $9.75
Upside: +105.13%
MapLight Therapeutics
Jul 27, 2026
Maintained: Buy
Price Target: $35 → $24
Current: $15.05
Upside: +59.47%
Cybin
Jul 22, 2026
Reiterated: Buy
Price Target: $42
Current: $8.04
Upside: +422.39%
AtaiBeckley
Jul 17, 2026
Reiterated: Buy
Price Target: $17 → $8
Current: $7.18
Upside: +11.50%
Biogen
Jul 15, 2026
Reiterated: Buy
Price Target: $245
Current: $208.98
Upside: +17.24%
Voyager Therapeutics
Jul 14, 2026
Reiterated: Buy
Price Target: $12
Current: $3.05
Upside: +294.09%
COMPASS Pathways
Jul 8, 2026
Reiterated: Buy
Price Target: $20
Current: $10.99
Upside: +81.98%
ACADIA Pharmaceuticals
Jun 29, 2026
Reiterated: Buy
Price Target: $32 → $36
Current: $26.25
Upside: +37.14%
Definium Therapeutics
Jun 29, 2026
Reiterated: Buy
Price Target: $60 → $58
Current: $42.15
Upside: +37.60%
Biohaven
Jun 18, 2026
Reiterated: Buy
Price Target: $21
Current: $13.57
Upside: +54.75%
May 19, 2026
Reiterated: Buy
Price Target: $27
Current: $2.48
Upside: +988.71%
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $4.84
Upside: +934.13%
May 15, 2026
Reiterated: Buy
Price Target: $39
Current: $28.29
Upside: +37.86%
May 8, 2026
Maintained: Buy
Price Target: $60
Current: $29.24
Upside: +105.23%
May 6, 2026
Reiterated: Buy
Price Target: $200
Current: $181.63
Upside: +10.11%
Apr 14, 2026
Reiterated: Buy
Price Target: $17
Current: $1.72
Upside: +891.25%
Sep 5, 2025
Reiterated: Buy
Price Target: $18
Current: $0.8101
Upside: +2,121.95%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $2.37
Upside: n/a
Jan 28, 2022
Downgraded: Hold
Price Target: $75 → $12
Current: $21.47
Upside: n/a
Apr 9, 2018
Maintained: Hold
Price Target: n/a
Current: $31.25
Upside: n/a
Jan 31, 2017
Upgraded: Buy
Price Target: n/a
Current: $34.63
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $17.87
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $19.09
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $10.42
Upside: n/a
Dec 18, 2015
Maintained: Buy
Price Target: $197.39
Current: $6.34
Upside: n/a